Skip to main content

Table 2 A multivariable Cox regression analysis # of BRMS1 expression and survival in nasopharyngeal carcinoma

From: Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival

 

For distant metastasis free survival

For overall survival

 

HR

95% CI

P*

HR

95% CI

P*

Training set

      

sex (men vs. women)

0.51

0.20-1.27

0.15

0.29

0.11-0.79

0.11

age (> 46 vs. ≤ 46)

1.16

0.55-2.46

0.54

1.11

0.53-2.35

0.72

WHO type (type I vs. type II)

0.89

0.20-3.99

0.80

1.31

0.26-5.02

0.81

TNM stage (III, IV vs. I, II)

3.91

1.35-11.29

0.01

2.59

0.99-6.83

0.04

BRMS1 (low vs. high)

4.54

2.11-9.76

0.00

6.56

2.97-14.41

0.00

VCA-IgA (≥ 1:320 vs. < 1:320)

0.73

0.26-2.03

0.93

0.41

0.15-1.13

0.21

EA-IgA (≥ 1:20 vs. < 1:20)

1.44

0.52-4.01

0.76

1.80

0.66-4.92

0.88

AER (≥ 63% vs. < 63%)

0.73

0.36-1.47

0.35

1.51

0.74- 2.51

0.07

Testing set

      

sex (men vs. women)

0.56

0.22-1.38

0.28

0.76

0.36-1.80

0.62

age (> 46 vs. ≤ 46)

1.25

0.65-2.43

0.47

1.54

0.77-3.10

0.14

WHO type (type I vs. type II)

1.05

0.13-8.39

0.60

0.67

0.08-5.60

0.42

TNM stage (III, IV vs. I, II)

3.19

1.24-8.21

0.02

3.91

1.38-11.11

0.01

BRMS1 (low vs. high)

3.31

1.69-6.47

0.00

4.39

2.14-9.01

0.00

VCA-IgA (≥ 1:320 vs. < 1:320)

0.47

0.19-1.15

0.97

0.44

0.18-1.10

0.71

EA-IgA (≥ 1:20 vs. < 1:20)

2.78

1.12-6.94

0.19

2.33

0.91-5.98

0.31

AER (≥ 63% vs. < 63%)

0.57

0.26-1.29

0.32

1.03

0.49-2.19

0.71

Overall patient population

      

sex (men vs. women)

0.63

0.34-1.18

0.18

0.57

0.30-1.07

0.15

age (> 46 vs. ≤ 46)

1.18

0.72-1.92

0.38

1.32

0.80-2.18

0.25

WHO type (type I vs. type II)

0.90

0.28-2.91

0.74

0.89

0.27-2.88

0.57

TNM stage (III, IV vs. I, II)

3.39

1.68-6.86

0.00

3.24

1.60-6.57

0.00

BRMS1 (low vs. high)

3.59

2.17-5.92

0.00

4.77

2.82-8.06

0.00

VCA-IgA (≥ 1:320 vs. < 1:320)

0.62

0.31-1.21

0.84

0.53

0.27-1.04

0.29

EA-IgA (≥ 1:20 vs. < 1:20)

1.91

0.95-3.85

0.16

1.64

0.82-3.29

0.72

AER (≥ 63% vs. < 63%)

1.20

0.70-2.07

0.36

1.69

1.00-2.86

0.04

  1. # The variables were selected using the backward Wald stepwise selection method. * The p values were calculated using an adjusted Cox regression model. The following parameters were included as covariates in each of these models: sex (men vs. women), age (> 46 vs. ≤ 46), WHO type (type I vs. type II), TNM stage (III and IV vs. I and II), BRMS1 expression (low vs. high) VCA-IgA (≥ 1:320 vs. < 1:320), EA-IgA (≥ 1:20 vs. < 1:20) and AER (≥ 63% vs. < 63%). VCA-IgA: viral capsid antigenimmunoglobulin A; EA-IgA: early antigenimmunoglobulin A; AER: antienzyme rate (AER) of Epstein-Barr virus (EBV) DNase-specific neutralizing antibody; HR: hazard ratio; CI: confidence interval.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us